{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087876","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.016265+00:00","generated_at":"2026-05-31T10:21:23.542333+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Iovance updates corporate presentation; FY24 product revenue guidance $160-165M, Q2 revenue $31.1M","bullets":["FY2024 product revenue guidance of $160-165 million; Q2 2024 net product revenue $31.1 million.","Cash and investments ~$450 million as of July 24, 2024, after ~$200M ATM equity raise in Q2-Q3 2024.","51 Authorized Treatment Centers as of Aug 8, 2024; >225M patient lives covered; >55 patients treated.","Pipeline: TILVANCE-301 Phase 3 frontline melanoma enrolling; IOV-LUN-202 NSCLC registrational data expected 2025.","IOV-END-201 Phase 2 proof-of-concept trial in endometrial cancer initiated; IOV-4001 PD-1 inactivated TIL in Phase 1/2."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087876","json":"https://secwatch.observer/filing/0001104659-24-087876.json","markdown":"https://secwatch.observer/filing/0001104659-24-087876.md","text":"https://secwatch.observer/filing/0001104659-24-087876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924087876/0001104659-24-087876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924087876/tm2421344d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:21:23.542333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}